文献速递肿瘤 PET/CT核素与放射性配体治疗

[18F]AlF-P16-093在原发性前列腺癌患者中的最佳药代动力学建模与简化定量方法确定

Determining the optimal pharmacokinetic modelling and simplified quantification method of [18F]AlF-P16-093 for patients with primary prostate cancer (PPCa).
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2024-01-29

本研究对8例原发性前列腺癌患者行动态PET/CT及注射后60分钟全身扫描,评估三种药代动力学模型并寻找简化定量方法。可逆双室模型(2T4K)为首选动力学模型,28-34分钟窗口的SURmean可充分近似总分布容积Vt(R2=0.949,P<0.01)。Vt和SURmean均与总血清PSA显著相关(P<0.01),提示30-60分钟单次静态PET成像用于前列腺癌诊断的可行性。

要点

  • 可逆双室模型(2T4K)是[18F]AlF-P16-093的首选药代动力学模型。
  • 28-34分钟窗口的SURmean可充分近似Vt(R2=0.949,P<0.01)。
  • Vt和SURmean均与总血清PSA显著相关(P<0.01)。

核心结论

  • 本研究提出了[18F]AlF-P16-093的优化药代动力学建模方法和简化采集方法,提示30-60分钟单次静态PET成像用于前列腺癌诊断的可行性。
  • 作者指出本研究中的图像衍生输入函数可能不反映真实的校正血浆输入函数,因此相关动力学参数估计的解释应谨慎。

研究设计与样本

  • 对8例原发性前列腺癌患者行动态PET/CT扫描,注射后60分钟行全身扫描。
  • 通过勾画原发前列腺和转移灶的感兴趣区获得时间-活性曲线(TACs)。
  • 评估三种考虑分数血容量(Vb)的房室模型(1T2K、2T3K、2T4K)以确定最佳动力学建模。
  • 基于静态摄取指标与最佳药代动力学分析获得的总分布容积(Vt)之间的相关性确定简化定量方法。

主要发现

  • 共评估17个前列腺内病灶、10个淋巴结和36个骨转移灶。
  • 视觉上肿瘤对比度增加并在最初几分钟内显示最陡峭上升,而背景活性随时间下降。
  • 可逆双室(2T4K)模型是指定示踪剂的首选动力学模型。
  • 病灶的动力学参数K1、k3、Vb和Vt均显著高于正常组织(P < 0.01)。
  • 基于图像的SURmean(肿瘤SUVmean与血液SUVmean之比)在28-34分钟窗口足以近似总分布Vt值(R2 = 0.949,P < 0.01)。

关键数值与推荐

  • 可逆双室(2T4K)模型为[18F]AlF-P16-093的首选动力学模型。
  • 28-34分钟窗口的SURmean可充分近似Vt(R2 = 0.949,P < 0.01)。
  • 病灶K1、k3、Vb和Vt均显著高于正常组织(P < 0.01)。
  • Vt和SURmean均与tPSA显著相关(P < 0.01)。

临床怎么用

  • 作者认为30-60分钟单次静态PET成像用于前列腺癌诊断具有可行性。
  • 作者指出图像衍生输入函数可能不反映真实校正血浆输入函数,相关动力学参数估计的解释应谨慎。

局限性

  • 本研究中的图像衍生输入函数可能不反映真实的校正血浆输入函数,因此相关动力学参数估计的解释应谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This paper discusses the optimization of pharmacokinetic modelling and alternate simplified quantification method for [18F]AlF-P16-093, a novel tracer for in vivo imaging of prostate cancer. METHODS: Dynamic PET/CT scans were conducted on eight primary prostate cancer patients, followed by a whole-body scan at 60 min post-injection. Time-activity curves (TACs) were obtained by drawing volumes of interest for primary prostatic and metastatic lesions. Optimal kinetic modelling involved evaluating three compartmental models (1T2K, 2T3K, and 2T4K) accounting for fractional blood volume (Vb). The simplified quantification method was then determined based on the correlation between the static uptake measure and total distribution volume (Vt) obtained from the optimal pharmacokinetic analysis. RESULTS: In total, 17 intraprostatic lesions, 10 lymph nodes, and 36 osseous metastases were evaluated. Visually, the contrast of the tumor increased and showed the steepest incline within the first few minutes, whereas background activity decreased over time. Full pharmacokinetic analysis revealed that a reversible two-compartmental (2T4K) model is the preferred kinetic model for the given tracer. The kinetic parameters K1, k3, Vb, and Vt were all significantly higher in lesions when compared with normal tissue (P < 0.01). Several simplified protocols were tested for approximating comprehensive dynamic quantification in tumors, with image-based SURmean (the ratio of tumor SUVmean to blood SUVmean) within the 28-34 min window found to be sufficient for approximating the total distribution Vt values (R2 = 0.949, P < 0.01). Both Vt and SURmean correlated significantly with the total serum prostate-specific antigen (tPSA) levels (P < 0.01). CONCLUSIONS: This study introduced an optimized pharmacokinetic modelling approach and a simplified acquisition method for [18F]AlF-P16-093, a novel PSMA-targeted radioligand, highlighting the feasibility of utilizing one static PET imaging (between 30 and 60 min) for the diagnosis of prostate cancer. Note that the image-derived input function in this study may not reflect the true corrected plasma input function, therefore the interpretation of the associated kinetic parameter estimates should be done with caution.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Zhao R, Xia Z, Ke M, et al. Determining the optimal pharmacokinetic modelling and simplified quantification method of [18F]AlF-P16-093 for patients with primary prostate cancer (PPCa). Eur J Nucl Med Mol Imaging. 2024. PMID: 38285206. doi:10.1007/s00259-024-06624-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。